Correlation Between UBS Plc and Mereo BioPharma

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both UBS Plc and Mereo BioPharma at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining UBS Plc and Mereo BioPharma into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between UBS plc and Mereo BioPharma Group, you can compare the effects of market volatilities on UBS Plc and Mereo BioPharma and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in UBS Plc with a short position of Mereo BioPharma. Check out your portfolio center. Please also check ongoing floating volatility patterns of UBS Plc and Mereo BioPharma.

Diversification Opportunities for UBS Plc and Mereo BioPharma

-0.69
  Correlation Coefficient

Excellent diversification

The 3 months correlation between UBS and Mereo is -0.69. Overlapping area represents the amount of risk that can be diversified away by holding UBS plc and Mereo BioPharma Group in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Mereo BioPharma Group and UBS Plc is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on UBS plc are associated (or correlated) with Mereo BioPharma. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Mereo BioPharma Group has no effect on the direction of UBS Plc i.e., UBS Plc and Mereo BioPharma go up and down completely randomly.

Pair Corralation between UBS Plc and Mereo BioPharma

Assuming the 90 days trading horizon UBS plc is expected to generate 0.21 times more return on investment than Mereo BioPharma. However, UBS plc is 4.82 times less risky than Mereo BioPharma. It trades about 0.27 of its potential returns per unit of risk. Mereo BioPharma Group is currently generating about -0.1 per unit of risk. If you would invest  875,600  in UBS plc on September 6, 2024 and sell it today you would earn a total of  52,100  from holding UBS plc or generate 5.95% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthWeak
Accuracy100.0%
ValuesDaily Returns

UBS plc   vs.  Mereo BioPharma Group

 Performance 
       Timeline  
UBS plc 

Risk-Adjusted Performance

18 of 100

 
Weak
 
Strong
Solid
Compared to the overall equity markets, risk-adjusted returns on investments in UBS plc are ranked lower than 18 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively uncertain basic indicators, UBS Plc may actually be approaching a critical reversion point that can send shares even higher in January 2025.
Mereo BioPharma Group 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Mereo BioPharma Group has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest uncertain performance, the Stock's basic indicators remain stable and the newest uproar on Wall Street may also be a sign of mid-term gains for the firm private investors.

UBS Plc and Mereo BioPharma Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with UBS Plc and Mereo BioPharma

The main advantage of trading using opposite UBS Plc and Mereo BioPharma positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if UBS Plc position performs unexpectedly, Mereo BioPharma can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Mereo BioPharma will offset losses from the drop in Mereo BioPharma's long position.
The idea behind UBS plc and Mereo BioPharma Group pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.

Other Complementary Tools

Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Transaction History
View history of all your transactions and understand their impact on performance
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets